Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

G. Amado, Rafael; Wolf, Michael; Peeters, Marc; Van Cutsem, Eric; Siena, Salvatore; J. Freeman, Daniel; Juan, Todd; Sikorski, Robert; Suggs, Sid; Radinsky, Robert; D. Patterson, Scott; Chang, David

doi:10.1200/jco.2007.14.7116

Public

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Published in Journal of Clinical Oncology • Mar 3, 2008

Authors:

Rafael G. Amado

Michael Wolf

Marc Peeters

Abstract

PURPOSE: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR anti...

Subject

Panitumumab

KRAS

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!